|
|
Volumn 104, Issue 11, 2012, Pages 800-801
|
|
Avastin saga reveals debate over clinical trial endpoints.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
BREAST TUMOR;
CLINICAL TRIAL (TOPIC);
DISEASE FREE SURVIVAL;
DRUG APPROVAL;
EUROPE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
METABOLISM;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
NOTE;
PATHOLOGY;
PHASE 3 CLINICAL TRIAL (TOPIC);
POSTMARKETING SURVEILLANCE;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
STANDARD;
TREATMENT OUTCOME;
UNITED STATES;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
DISEASE-FREE SURVIVAL;
DRUG APPROVAL;
EUROPE;
HUMANS;
MOLECULAR TARGETED THERAPY;
NEOADJUVANT THERAPY;
PRODUCT SURVEILLANCE, POSTMARKETING;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84864751467
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djs265 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|
